Stockholm 3rd October 2018 - Peptonic Medical AB (publ) (’Peptonic’) or (’Company’) today announced that it has received a launch order for the Finnish version of VagiVital® from Orion Pharma. The value of the order is in excess of one million SEK, and it shall be delivered by the end of this year.
- This is another historical event in Peptonic. That Orion Pharma has decided to launch Peptonic’s non-prescription product for the treatment of vaginal dryness is an accolade to the clinical documentation and quality of the product, says Johan Inborr, CEO of Peptonic Medical. Soon women in Finland will have access to a new, hormone-free, safe and effective treatment for vaginal dryness.
Orion Pharma will market VagiVital® under its own brand in Finland. Pharmacies and pharmacy webshops will serve as the main distribution channels.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 3rd October 2018.
VagiVital® is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
Peptonic Medical is launching VagiVital® as a non-prescription self-care product in 2018.
About Peptonic Medical
Peptonic Medical is an innovative Swedish development company. Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after.
VagiVital® is a trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy.
The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
In July 2014, Peptonic Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.
For more information: www.peptonicmedical.com